Pterostilbene Biosynthesis via Enzymatic Pathway Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an efficient and scalable approach for biosynthetic production of pterostilbene, a compound with potential anti-cancer, anti-hypercholesterolemia, and anti-diabetic properties, as the existing pathways are not effectively harnessed for industrial production.
Innovation Solution
Expression of 4-coumarate:coenzyme A ligase (4CL), stilbene synthase (STS), and resveratrol O-methyltransferase (ROMT) genes in cellular systems like yeast or bacteria, along with feeding p-coumaric acid or resveratrol, to facilitate the biosynthetic conversion into pterostilbene.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional extraction methods are used to obtain pterostilbene from natural sources, then the compound can be obtained, but the production efficiency is low and cannot meet industrial scale requirements
Solution Approach 1:
The patent utilizes engineered microbial cells (yeast or bacteria) that contain the complete biosynthetic pathway for pterostilbene production. These cells autonomously convert supplied p-coumaric acid into pterostilbene through their metabolic machinery, eliminating the need for complex extraction processes from natural sources and enabling scalable industrial production.
Solution Approach 2:
The patent introduces resveratrol as an intermediate compound in the biosynthetic pathway. The engineered cells first produce resveratrol from p-coumaric acid, then convert it to pterostilbene. This intermediary step allows for optimized control of the biosynthetic pathway and enables the use of well-characterized enzymatic reactions (4CL, STS, and ROMT) to achieve efficient production.
2Productivity
If the complete biosynthetic pathway (4CL, STS, ROMT) is expressed in a cellular system, then pterostilbene production is enabled, but the system complexity increases
Solution Approach 1:
The patent combines three separate biosynthetic genes (4CL, STS, and ROMT) into a single engineered cellular system. By merging these pathways into one organism, the patent creates an integrated biosynthetic factory that converts p-coumaric acid to pterostilbene through coordinated expression of all necessary enzymes, simplifying the overall production system compared to using separate extraction or chemical synthesis methods.
Solution Approach 2:
The engineered microbial cells perform multiple functions: they metabolize p-coumaric acid, synthesize resveratrol, convert it to pterostilbene, and secrete or accumulate the final product. This multi-functionality within a single cellular system enables a streamlined production process that replaces multiple separate operations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the industrial production of pterostilbene by converting resveratrol into pterostilbene through a controlled cellular system, demonstrating enhanced conversion efficiency and potential for large-scale production.
Implementation Method 1
resveratrol O-methyltransferase (ROMT) could catalyze the direct conversion of resveratrol into pterostilbene
Implementation Method 2
Pterostilbene is produced by the action of 4-coumarate-CoA ligase (4CL), stilbene synthase (STS) and resveratrol O-methyltransferase (ROMT)
Data Source
AI summary
A biosynthetic method of making pterostilbene including expressing a 4-coumaratexoenzyme A ligase (4CL) in a cellular system, expressing a stilbene synthase (STS) in the cellular system, expressing a resveratrol O-methyltransferase (ROMT) in the cellular system, feeding p-coumaric acid to the cellular system, growing the cellular system in a medium, and producing pterostilbene.